Advertisement
Screener

Organon & Co. (OGN) Debt / Equity

Organon & Co. (OGN) Debt / Equity

  • 2025-03-31: Debt/Equity Ratio 16.52.
  • 2024-12-31: Debt/Equity Ratio 18.81.
  • 2024-09-30: Debt/Equity Ratio 17.75.
  • 2024-06-30: Debt/Equity Ratio 60.11.

Complete source-backed debt/equity ratio history.

Available history
2020-12-31 to 2025-03-31
Data captured

Historical Debt/Equity Ratio

DateDebt/Equity Ratio
2025-03-3116.52
2024-12-3118.81
2024-09-3017.75
2024-06-3060.11
2024-03-31181.54
2023-12-31-125.14
2023-09-30-14.69
2023-06-30-15.73
2023-03-31-11.82
2022-12-31-9.99
2022-09-30-8.16
2022-06-30-7.82
2022-03-31-7.28
2021-12-31-6.06
2021-09-30-5.75
2021-06-30-4.83
2020-12-310

Annual Debt/Equity Ratio

DateDebt/Equity Ratio
2024-12-3118.81
2023-12-31-125.14
2022-12-31-9.99
2021-12-31-6.06
2020-12-310

Similar stocks

Stock NameCountryMarket CapPE Ratio
IDEAYA Biosciences, Inc. (IDYA)United States$3.540B-20.52
Xenon Pharmaceuticals Inc. (XENE)$3.684B-14.27
ACADIA PHARMACEUTICALS INC (ACAD)United States$3.823B11.45
Amylyx Pharmaceuticals, Inc. (AMLX)United States$3.361B-13.15
AbCellera Biologics Inc. (ABCL)$3.879B-14.59
Enliven Therapeutics, Inc. (ELVN)United States$3.307B-35.07
Arcutis Biotherapeutics, Inc. (ARQT)United States$3.303B115.47
Arcus Biosciences, Inc. (RCUS)United States$3.188B-8.52
Dyne Therapeutics, Inc. (DYN)United States$3.084B-7.09
Tango Therapeutics, Inc. (TNGX)United States$4.154B-42.53